protein and glp 1 GLP-1 + What to Know About Protein

Contamination risk with compounded/DIY products: This is the bigger practical concern

Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes

Ravassa S, Zudaire A, Carr RD, Diez J

CJC-1295, Ipamorelin, and Tesamorelin exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice

10.1186/s40168-021-01062-5 11 CavinatoM.Jansen-DrrP

These findings are meaningful though most studies are small, follow-up periods are limited, and there is not yet sufficient evidence to recommend GLP-1 medications as a treatment for eating disorder symptoms ( Bartel et al., Int J Eating Disorders, 2024 )